Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review
Pharmaceuticals · 22.07.2025 · 18 (8) · 1082
DOI: 10.3390/ph18081082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.07.2025. Verfasst von Laci M Turner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: This review discusses the resistance mechanisms in the tumor microenvironment (TME) of malignant melanoma that disrupt the efficacy of immune checkpoint inhibitors (ICIs). In this review, we focus on the roles of immune cells, including tumor-infiltrating lymphocytes (TILs), macrophages, dendritic cells, and other signaling pathways. We explore the interplay between innate and adaptive immunity in the TME and tumor intrinsic resistance mechanisms, such as β-catenin, which has future implications for the usage of ICIs in patients with therapy-resistant tumors.
Methods
A total of 1052 studies were extracted from the PubMed database searching for keywords and phrases that included [melanoma AND immune checkpoint inhibitor resistance]. After a title/abstract and full-text review, 101 studies were identified that fit the inclusion/exclusion criteria.
Results
Cancer-associated fibroblasts (CAFs), M2 macrophages, and myeloid-derived suppressor cells (MDSCs) are significant in remodeling the TME to promote melanoma growth. Melanoma resistance to ICIs is complex and involves TME alterations, tumor intrinsic factors, and immune evasion. Key components of resistance include reduced CD8+ T cell infiltration, decreased host immune response, and immunosuppressive cytokines.
Conclusions
Predictive biomarkers and specific models are the future of individualized melanoma management and show great promise in their approach to targeted therapy production. Tumor profiling can be utilized to help predict the efficacy of ICIs, and specific biomarkers predicting therapy responses are instrumental in moving towards personalized and more efficacious medicine. As more melanoma resistance emerges, alternative and combinatorial therapy based on knowledge of existing resistance mechanisms will be needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, 1670 University Blvd., VH566A, Birmingham, AL 35294, USA.
ORCID-Profile: Laci M Turner, Hanna Terhaar, Emily Grant, Nabiha Yusuf
Zitieren
APA
Turner, L. M., Terhaar, H., Jiminez, V., Anderson, B. J., Grant, E., & Yusuf, N. (2025). Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review. Pharmaceuticals, 18(8), 1082. https://doi.org/10.3390/ph18081082
Vancouver
Turner LM, Terhaar H, Jiminez V, Anderson BJ, Grant E, Yusuf N. Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review. Pharmaceuticals. 2025;18(8):1082. doi:10.3390/ph18081082
BibTeX
@article{Turner2025,
author = {Turner, Laci M and Terhaar, Hanna and Jiminez, Victoria and Anderson, Bailey J and Grant, Emily and Yusuf, Nabiha},
title = {Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1082},
doi = {10.3390/ph18081082}
}
EUVIMED